Pregled bibliografske jedinice broj: 395223
Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome
Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome // Clinical Lymphoma & Myeloma, 7 (2007), 9; 590-593 (međunarodna recenzija, kratko priopcenje, znanstveni)
CROSBI ID: 395223 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome
Autori
Dumić, Miroslav ; Radman-Livaja, Ivo ; Krnić, Nevena ; Nola, Marin ; Kušec, Rajko ; Begović, Davor ; Labar, Boris ; Radoš, Marko
Izvornik
Clinical Lymphoma & Myeloma (1557-9190) 7
(2007), 9;
590-593
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kratko priopcenje, znanstveni
Ključne riječi
Nijmegen syndrome; diffuse large B-cell non-Hodgkin lymphoma; chemotherapy; rituximab
Sažetak
A 17-year-old Croatian boy with Nijmegen breakage syndrome (NBS) who developed diffuse large B-cell non-Hodgkin lymphoma is presented. The majority of the patients with this rare autosomal recessive disease are of Slavic origin and, in most of them, the disease is caused by NBS1 mutation 657de15, as was found in our patient. Nijmegen breakage syndrome is characterized by microcephaly, growth retardation, abnormal facial appearance, spontaneous chromosomal rearrangements, immunodeficiency, and a high predisposition to cancer development, predominantly lymphoma. Because of increased sensitivity to radiation therapy and chemotherapy, the treatment of malignancies in patients with NBS can be difficult. To our knowledge, our patient is the first with NBS reported in the literature who was successfully treated for diffuse large B-cell lymphoma with the anti-CD20 monoclonal antibody rituximab in addition to a modified dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy. He has been in complete remission for 3 years after finishing the treatment
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-0353 - Novi pristupi dijagnostici nasljednih bolesti (Begović, Davor, MZOS ) ( CroRIS)
108-0000000-0359 - Nasljedne endokrine bolesti u djece (Dumić, Miroslav, MZOS ) ( CroRIS)
108-1081872-1913 - LEUKEMIJE I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Duraković, Nadira, MZOS ) ( CroRIS)
108-1980955-3094 - Genetika i funkcija hematopoeze i mikrookoliša Ph- mijeloproliferativnih bolesti (Kušec, Rajko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb
Profili:
Boris Labar
(autor)
Marko Radoš
(autor)
Miroslav Dumić
(autor)
Davor Begović
(autor)
Ivo Radman-Livaja
(autor)
Marin Nola
(autor)
Rajko Kušec
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE